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Shinya Watanabe,1 Ryuhei Hayashi,1,2,3,12,* Yuzuru Sasamoto,4 Motokazu Tsujikawa,5 Bruce R. Ksander,6
Markus H. Frank,7,8,9 Andrew J. Quantock,10 Natasha Y. Frank,4,8,11 and Kohji Nishida1,3,*
1Department

SUMMARY

Human induced pluripotent stem cells (hiPSCs) can generate a multiplicity of organoids, yet no compelling evidence currently exists as to whether or not these
contain tissue-specific, holoclone-forming stem cells. Here, we show that a subpopulation of cells in a hiPSC-derived corneal epithelial cell sheet is positive for
ABCB5 (ATP-binding cassette, sub-family B, member 5), a functional marker of
adult corneal epithelial stem cells. These cells possess remarkable holocloneforming capabilities, which can be suppressed by an antibody-mediated
ABCB5 blockade. The cell sheets are generated from ABCB5+ hiPSCs that first
emerge in 2D eye-like organoids around six weeks of differentiation and display
corneal epithelial immunostaining characteristics and gene expression patterns,
including sustained expression of ABCB5. The findings highlight the translational potential of ABCB5-enriched, hiPSC-derived corneal epithelial cell sheets
to recover vision in stem cell-deficient human eyes and represent the first
report of holoclone-forming stem cells being directly identified in an hiPSCderived organoid.
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Previously, we reported how human induced pluripotent stem cells (hiPSCs) in defined culture conditions
can generate a two-dimensional eye-like organoid, referred to as an SEAM (self-formed, ectodermal,
autonomous, multi-zone) (Hayashi et al., 2016, 2017, 2018). In a number of respects, SEAM formation
mimics whole-eye development in that the innermost central area (zone 1) forms first, followed by the emergence of three more radially distant, concentric cell populations: zones 2–4 (Figures 1A and 1B). Specifically, cells in zone 1 are akin to presumptive neuroectoderm; zone 2 cells are developmental analogs of
neural eye tissues comprising the neuroretina, neural crest, and retinal pigment epithelium (RPE); cells in
zone 3 have characteristics of corneal and conjunctival epithelial cells, while zone 4 cells resemble general
surface ectodermal cells that will likely differentiate into epidermal keratinocytes. Further investigation of
cells in SEAM zone 3 indicated that they could be sorted by flow cytometry and that those that were positive
for the cell surface makers, SSEA4 and CD104, and negative for CD200 (i.e. SSEA4+/CD104+/CD200-)
possessed corneal epithelial characteristics and could be fashioned into functional corneal epithelial cell
sheets (Hayashi et al., 2016, 2017, 2018). Our investigations have also identified ABCB5 as a functional
marker of adult corneal epithelial stem cells (Frank et al., 2003; Ksander et al., 2014; Sasamoto et al.,
2018, 2020).
Vision loss arising from a corneal epithelial stem cell deficiency invariably requires surgical intervention if a
patient’s sight is to be restored. Contemporary treatments often involve the ex vivo expansion of corneal
epithelial stem cells obtained from the stem cell niche at the edge of the cornea (a region of the eye known
as the limbus) to form a functional corneal epithelial cell sheet that can be grafted onto the eye (Pellegrini
et al., 1997; Lindberg et al., 1993; Ang et al., 2007; Schwab et al., 2000). It has been suggested, based on
retrospective immunostaining of expanded corneal epithelial cell sheets with the proposed stem cell
marker, p63, that a successful surgical outcome correlates with the number of stem cells likely to be present
in the expanded sheet (Rama et al., 2010). However, establishing whether or not holoclone-forming stem
cells are present in an expanded corneal epithelial cell sheet—or in any other hiPSC-derived organoid for
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Figure 1. ABCB5+ corneal epithelial cells can be induced and isolated from hiPSCs
(A) Strategy to generate and sort hiPSC-derived cells. CDM, corneal differentiation medium; CEM, corneal epithelium maintenance medium; DM,
differentiation medium; d, day(s); w, week(s).
(B) SEAM of hiPSCs mimics ocular development. CNS, central nervous system; NR, neuroretina; RPE, retinal pigment epithelium; NC, neural crest; LE; lens;
CE, corneal epithelium; EK, epidermal keratinocyte.
(C) ABCB5 expression in SEAM zones 1–4 during differentiation (each n = 5 independent experiments). Error bars are standard deviation.
(D) Flow cytometric analysis of the differentiated SEAM. 0.71 G 0.62% of hiPSC-derived corneal epithelial cells (SSEA4+/CD104+/CD200-) were ABCB5+.
Data shown are representative of 58 independent cell sorting experiments.

that matter—has not been achieved. Here, we combine the expansion of hiPSCs into SEAMs with cell sorting based on ABCB5 specificity to investigate this issue.

RESULTS
ABCB5+ corneal epithelial cells can be induced and isolated from hiPSCs
ABCB5 mRNA was detected at 6 weeks in SEAM zone 2 and at 7 weeks in zone 3 and was maintained until
12 weeks of differentiation in both zones (Figure 1C). In contrast, no expression was seen in zone 1 or zone 4
throughout the whole cultivation period. Flow cytometry revealed that 0.71 G 0.62% of SSEA4+/CD104+/
CD200- corneal epithelial cells derived from zone 3 were ABCB5+ (Figure 1D). Of note, a similar percentage
of ABCB5+ cells were found in corneal limbal epithelial cells isolated from a human cadaveric donor eye
(Sasamoto et al., 2020). These findings revealed that ABCB5+ corneal epithelial cells can be induced and
isolated from hiPSCs via an SEAM and that the localization of ABCB5 expression in an SEAM mirrors
that in human eyes, where it is found in the RPE and limbal epithelium (Ksander et al., 2014; Chen et al.,
2005). We also observed that ABCB5 expression first appears midway through SEAM formation, which
would be consistent with the notion that ABCB5 is associated with adult stem cell activity during human
ocular differentiation.

hiPSC-derived ABCB5+ corneal epithelial cells have self-renewal potential
To ascertain the self-renewal potential of ABCB5+ and ABCB5- cells isolated from SEAM-derived corneal
epithelial cells, we performed colony-forming assays and holoclone assays (Figures S1A and S1B). These
indicated that the colony-forming efficiency was greater and the colony size was larger for ABCB5+ cells
when compared to ABCB5- cells (13.5 G 3.8% vs. 7.5 G 2.4%, P < 0.05; 1.56 G 0.65 mm vs. 0.79 G
0.43 mm, P < 0.05, respectively) (Figure 2A). Moreover, holoclone formation was a characteristic of
ABCB5+ cells but not ABCB5- cells (13.8 G 4.0% vs. 0.0 G 0.0%, P < 0.05) (Figure 2B), and even though
the number of ABCB5+ cells in the SEAM-derived corneal epithelial cells was few, the holoclone-forming
capability resided exclusively in this subpopulation. A gene expression analysis by quantitative real-time
reverse-transcriptase PCR (qRT-PCR) further showed that DNp63, a widely used marker of corneal epithelial stem cells (Rama et al., 2010; Pellegrini et al., 2001), was enriched in ABCB5+ cell-derived colonies
compared to ABCB5- cell-derived colonies (5.17 G 1.77% vs. 4.30 G 1.69%, P < 0.05) (Figure 2C). The
expression of KRT12 and PAX6, known markers of differentiated corneal epithelial cells, was also
lower in ABCB5+ cell-derived colonies (4.05 G 12.41% vs. 11.32 G 24.31%, P < 0.05; 0.96 G 2.30% vs.
2.51 G 3.63%, P < 0.05, for ABCB5+ and ABCB5-, respectively) (Figure 2C). These findings reflect the undifferentiated status of SEAM-derived ABCB5+ corneal epithelial cells and their holoclone-forming
capacity.

ABCB5 blockade inhibits self-renewal of hiPSC-derived ABCB5+ corneal epithelial cells
To further investigate the connection between ABCB5 and SEAM-derived corneal epithelial cell selfrenewal, colony-forming assays and holoclone assays were performed with and without the inclusion of
a specific monoclonal antibody (mAb)-mediated ABCB5 blockade (Ksander et al., 2014; Wilson et al.,
2014; Lutz et al., 2016; Schatton et al., 2015) (Figure 3A). This revealed that a consecutive 10-day treatment
of SEAM-derived ABCB5+ cells with 50 mg/mL of anti-ABCB5 blocking mAb (clone 3C2-1D12) suppressed
colony formation to levels that were significantly below those of the control, non-mAb-treated group (1.6 G
0.7% vs. 12.2 G 5.6%, P < 0.05) (Figure 3B). Holoclone formation, moreover, was found to be completely
inhibited in the anti-ABCB5 mAb-treated group compared with the control group (0.0 G 0.0% vs. 9.0 G
5.4%, P < 0.05) (Figure 3C), which is supportive of a defining role for ABCB5 in the self-renewal potential
of hiPSC-derived corneal epithelial stem cells.
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Figure 2. hiPSC-derived ABCB5+ corneal epithelial cells have self-renewal potential
(A) Representative colony-forming assays of seven independent experiments for ABCB5+/ABCB5- hiPSC-derived corneal
epithelial cells plus colony-forming efficiency and colony diameter (left panel, n = 7 independent experiments; right
panel, ABCB5+; n = 172 colonies: ABCB5-; n = 93 colonies from 4 independent experiments).
(B) Representative images of a holoclone and a non-holoclone and percentage of holoclones (n = 4 independent
experiments). See also Figure S1.
(C), Gene expression analysis for stem cell marker DNp63 and differentiated corneal epithelium-related markers PAX6
and KRT12 in ABCB5+/ABCB5- colonies (ABCB5+; n = 131 colonies: ABCB5-; n = 55 colonies from 6 independent
experiments). *p < 0.05, Wilcoxon signed-rank test. Error bars are standard deviation.

Corneal epithelial cell sheets can be fabricated from hiPSC-derived ABCB5+/ABCB5- cells
It was discovered that ex vivo expanded corneal epithelial cell sheets could be fabricated from both
ABCB5+ and ABCB5- cells obtained from SEAM zone 3, although the ABCB5+ cell-derived sheets
were more highly stratified and significantly thicker (10.41 G 0.88 mm vs. 5.65 G 0.81 mm, P < 0.05) (Figure 4A). The corneal epithelial marker, KRT12, the ocular cell marker, PAX6, and the epithelial/surface
ectodermal marker, p63, were all identified in the ABCB5+ and ABCB5- cell-derived sheets (Figure 4B).
This represents a typical corneal epithelial immunostaining pattern, the validity of which was reinforced
by the results of a gene expression analysis of the cell sheets (Figure 4C). The fact that the pattern of
gene expression changes seen in the hiPSC-derived colonies, on the one hand, and in the expanded
corneal epithelial cell sheets, on the other hand, differs is perhaps reflective of a process of differentiation/maturation of cells in the cell sheets (21–28 days cultivation) compared to cells in the colonies
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Figure 3. ABCB5 blockade inhibits self-renewal in hiPSC-derived ABCB5+ corneal epithelial cells
(A) Schematic representation of mAb-mediated ABCB5 blocking followed by colony-forming assay (CFA) and holoclone
assay (HA) for the ABCB5+ hiPSC-derived corneal epithelial cells (iCECs). Sorted ABCB5+ iCECs were treated with antiABCB5 blocking mAb or isotype control IgG for 10 consecutive days from the initial day of sorting.
(B) Representative images of CFA after treatment with anti-ABCB5 blocking mAb or isotype control IgG (n = 4
independent experiments) and colony-forming efficiency after the treatments (n = 4 independent experiments).
(C) Representative images of a holoclone and a non-holoclone after antibody treatment and percentage of holoclones
after treatments with anti-ABCB5 blocking mAb or isotype control IgG (n = 4 independent experiments). *p < 0.05,
Wilcoxon signed-rank test. Error bars are standard deviation.

(10–12 days cultivation). Indeed, the culture medium used for cell sheet fabrication in the current study is
the same as that employed previously to generate mature corneal epithelial cell sheets (Miyashita et al.,
2013; Hayashi et al., 2016, 2017). Alternative culture conditions more suited to stem cell cultivation would
presumably lessen the maturation propensity of cells in the expanded cell sheets. Immunostaining also

iScience 24, 102688, June 25, 2021

5

ll

OPEN ACCESS

A

B

C

Figure 4. Corneal epithelial cell sheets can be fabricated from hiPSC-derived ABCB5+/ABCB5- cells
(A) Hematoxylin and eosin (H&E) staining of cell sheets fabricated from ABCB5+/ABCB5- hiPSC-derived corneal epithelial
cells (iCECs). Scale bar, 50 mm. Comparative thickness of cell sheets fabricated from hiPSC-derived ABCB5+/ABCB5- cells.
(n = 10 measurements from 1 experiment). *p < 0.05, Wilcoxon signed-rank test. Error bars are standard deviation.
(B) Immunostaining for ABCB5 and ocular epithelial markers (green) in ABCB5+/ABCB5- iCEC-derived sheets. ABCB5,
stem cell marker; KRT12, corneal epithelial marker, PAX6, ocular cell marker; p63, epithelial/surface ectodermal markers;
KRT13, conjunctival epithelial marker; MITF, retinal pigment epithelium (RPE) marker. Nuclei, red. Scale bar, 50 mm.
Dotted lines indicate border between cell sheets and culture inserts.
(C) Gene expression analysis for corneal epithelial stem cell markers and corneal epithelium-related markers in ABCB5+/
ABCB5- iCEC-derived sheets (n = 3 independent experiments). Error bars are standard deviation.

disclosed that neither the conjunctiva-specific keratin, KRT13, nor the RPE marker, MITF, was detected
in the ABCB5+ or ABCB5- cell-derived sheets (Figure 4B), suggesting that no contamination with
non-corneal epithelial cells occurred during the fabrication of the hiPSC-derived corneal epithelial cell
sheets.
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DISCUSSION
Here, we report the successful isolation of ABCB5+ corneal epithelial cells from hiPSCs via an SEAM. Collectively, our data indicate that ABCB5+ corneal epithelial cells possess functional stem cell characteristics,
namely a high holoclone-forming propensity accompanied by the expression of a corneal epithelial
stem cell marker, DNp63, and the capability to differentiate and form the corneal epithelium (Rama
et al., 2010; Pellegrini et al., 1999, 2001). The identification of ABCB5+ stem cells in an SEAM-derived
corneal epithelium represents the first definitive report of holoclone-forming human stem cells in an organoid originating from hiPSCs. This has theoretical and practical relevance in the fields of stem cell biology
and regenerative medicine. In particular, the results suggest that ABCB5+ SEAM-derived corneal epithelial
stem cells are similar in nature to the population of adult corneal epithelial stem cells in human eyes, which
can differentiate into transient amplifying cells and drive corneal epithelial turnover and repair (Lehrer
et al., 1998). Translational relevance lies in the fact that although surgeries to regain vision in eyes blinded
by a corneal epithelial stem cell deficiency already exist (Pellegrini et al., 1997; Lindberg et al., 1993; Ang
et al., 2007; Schwab et al., 2000), the corneal epithelial cell sheets that are used in contemporary graft surgery are fabricated from corneal epithelial cells obtained from a small biopsy of corneal epithelial cells
taken from the limbal stem cell niche of a healthy eye or from the limbus of postmortem donor tissue
sourced from an eye bank. The desire to avoid invasive biopsies of healthy eyes, aligned to the worldwide
shortage of donated tissue (Sasamoto et al., 2020; Gain et al., 2016), makes the prospect of generating
hiPSC-derived corneal epithelial cell sheets for transplant surgery an attractive one. This is especially
true when we remember that hiPSC-derived graft tissue containing corneal epithelial stem cells can be
applied for patients with bilateral disease whose limbal stem cell niche has been destroyed in both eyes
and for whom an autograft using a biopsy of healthy would otherwise not be an option. Previously, we
discovered that transplantation of hiPSC/SEAM-derived corneal epithelial cell sheets onto experimental
ocular surface wounds in rabbit eyes could recover ocular surface function (Hayashi et al., 2016), and we
have recently started to perform a small series of first-in-human corneal epithelial graft surgeries using
hiPSC/SEAM-derived corneal epithelial cell sheets as part of a clinical trial (UMIN000036539) that has
real potential to revolutionize the treatment of corneal blindness caused by a corneal epithelial stem
cell deficiency. The current discovery that the fabricated sheets do, indeed, contain holoclone-forming
corneal epithelial stem cells represents a major advance in our knowledge, which provides us with confidence in the concept of the translational approach and demonstrates that functional stem cells can be
formed in organoids derived from hiPSCs.

Limitations of the study
We demonstrated that hiPSC-derived ABCB5+ corneal epithelial stem cells possess self-renewal potency
within corneal epithelial cell sheets formed in vitro. We reason that the hiPSC-derived ABCB5+ cells will
likely contribute to the successful repair of an injured corneal surface after epithelial cell sheet graft surgery,
but this has not been proven. In vivo experiments using experimental ocular surface wounds in animal eyes
would be required to corroborate this supposition.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE

SOURCE

IDENTIFIER

Rabbit anti-PAX6

Covance Research Products Inc

Cat#PRB-278P; RRID:AB_291612

Mouse anti-p63

Santa Cruz Biotechnology

Cat#sc-8431; RRID:AB_628091

Mouse anti-ABCB5

Ksander et al., 2014

N/A

Goat anti-KRT12

Santa Cruz Biotechnology

Cat#sc-17098; RRID:AB_639266

Mouse anti-KRT13

Abcam

Cat#ab16112; RRID:AB_302267

Mouse anti-MITF

Exalpha Biologicals

Cat#X2398M

Donkey anti-mouse IgG Alexa Fluor 488

Life Technologies

Cat#A-21202; RRID:AB_141607

Life Technologies

Cat#A-21206; RRID:AB_141708

Life Technologies

Cat#A-11055; RRID:AB_2534102

Mouse anti-SSEA4 FITC conjugate

BioLegend

Cat#330410; RRID:AB_1089204

Mouse anti-CD104 PE conjugate

BioLegend

Cat#327808; RRID:AB_2129146

Mouse anti-CD200 PE-Cy7 conjugate

BD PharMingen

Cat#624052

StemFit

Ajinomoto

Cat#AK03N

iMatrix-511 (LN511E8)

Nippi

Cat#892012

GMEM

Life Technologies

Cat#11710-035

Cnt-Prime (w/o; EGF and FGF)

CELLnTEC Advanced Cell Systems

Cat#CnT-PR-EF

DMEM/F12 (1:1)

Life Technologies

Cat#11320-033

DMEM (high glucose, pyruvate, no glutamine)

Life Technologies

Cat#10313-021

Antibodies

conjugate
Donkey anti-rabbit IgG Alexa Fluor 488
conjugate
Donkey anti-goat IgG Alexa Fluor 488
conjugate

Chemicals, peptides, and recombinant proteins

Ham’s F-12 Nutrient Mix

Life Technologies

Cat#11765062

Y-27632

Wako

Cat#034-24024

Recombinant Human KGF

Wako

Cat#112-00813

B27 supplement

Life Technologies

Cat#17504-044

Knockout serum replacement (KSR)

Life Technologies

Cat#10828-028

Sodium pyruvate

Life Technologies

Cat#11360-070

Non-essential amino acids

Life Technologies

Cat#11140-050

Penicillin-streptomycin

Life Technologies

Cat#15140-122

Hydrocortisone sodium succinate

Phizer

Cat#872452

L-Glutamine

Life Technologies

Cat#25030149

2-Mercaptoethanol

Life Technologies

Cat#21985-023

Monothioglycerol

Wako

Cat# 195-15791

4% (wt/vol) Paraformaldehyde (PFA)

Wako

Cat# 163-20145

10% formaldehyde neutral buffer solution

Wako

Cat#062-01661

Methanol

Wako

Cat#131-01826

Hoechst 33342

Wako

Cat#346-07951

TrypLE Express

Life Technologies

Cat#12605-010

Mitomycin C (Medicine)

Kyowa Hakko Kirin

N/A

FBS

Life Technologies

Cat#12483-020

phosphate buffer solution

(Continued on next page)
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Continued

REAGENT or RESOURCE

SOURCE

3,3’,5-Triiodo-l-thyronine sodium salt

Sigma-Aldrich

IDENTIFIER
Cat#T5516

Cholera toxin

List Biological Laboratory

Cat#100B

Insulin transferrin selenium

Life Technologies

Cat#41400045

Rhodamine B

Wako

Cat#180-00132

Tissue-Tek OCT compound

Sakura finetek Japan

Cat#4583

D-PBS

Wako

Cat#045-29795

TBS(Tris-Buffered Saline)powder

TaKaRa Bio

Cat#T903

Triton X-100

Sigma-Aldrich

Cat#T8787-100ML

Normal donkey serum

Jackson ImmunoResearch

Cat#017-000-121

Human: iPS cell line 201B7

RIKEN Bio Resource Cente

Cat#HPS0063; RRID:CVCL_A324

Mouse: 3T3-J2 cell line

H. Green, Harvard Medical School, Boston, MA

N/A

Taqman probe ABCB5 (Hs02889060_m1)

Life Technologies

Cat#4331182

Taqman probe KRT12 (Hs00165015_m1)

Life Technologies

Cat#4331182

Experimental models: cell lines

Oligonucleotides

Taqman probe PAX6 (Hs00240871_m1)

Life Technologies

Cat#4331182

Taqman probe DNp63 (Hs00978339_m1)

Life Technologies

Cat#4331182

Taqman probe GAPDH (Hs99999905_m1)

Life Technologies

Cat#4331182

BD FACSDiva Software v8.0.3

BD Biosciences

RRID:SCR_001456

JMP software program v14.0.0

SAS institute

RRID:SCR_014242

ImageJ v1.51k

National Institutes of Health

RRID:SCR_003070

Software and algorithms

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to, and will be fulfilled upon
reasonable request, by the lead contact, Ryuhei Hayashi (ryuhei.hayashi@ophthal.med.osaka-u.ac.jp).

Materials availability
This study did not generate new unique reagents.

Data and code availability
The authors declare that all relevant data are available within the article and its Supplemental information
files or from the corresponding author upon reasonable request. This study did not generate new code.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
hiPSCs (cell line 201B7) were purchased from the RIKEN Bio Resource Center (Tsukuba, Japan) and cultivated in a feeder-free system in the presence of laminin-511 E8 fragments (LN511E8; Nippi, Tokyo, Japan)
and serum-free medium (StemFit; Ajinomoto, Tokyo, Japan) (Hayashi et al., 2016, 2017; Takahashi et al.,
2007; Nakagawa et al., 2014; Miyazaki et al., 2012).

METHOD DETAILS
Differentiation of hiPSCs using the SEAM method
The fabrication of SEAMs from hiPSCs was performed according to our previously reported method (Hayashi et al., 2016, 2017). Briefly, hiPSCs were cultivated for 12-14 weeks on LN511E8-coated (0.5 mg/cm2)
plates in serum-free differentiation medium (DM), corneal differentiation medium (CDM), and corneal
epithelium maintenance medium (CEM) (Hayashi et al., 2016, 2017) (Figure 1A). DM consists of GMEM
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(Life Technologies, Carlsbad, CA) supplemented with 10% knockout serum replacement (KSR; Life Technologies), 1 mM sodium pyruvate (Life Technologies), 0.1 mM non-essential amino acids (Life Technologies), 2 mM L-glutamine (Life Technologies), 1% penicillin-streptomycin solution (Life Technologies) and
55 mM 2-mercaptoethanol (Life Technologies). CDM is diluted 1:1 in DM and Cnt-PR (without EGF or
FGF2) (CELLnTEC Advanced Cell Systems, Bern, Switzerland) supplemented with 10 ng/mL keratinocyte
growth factor (KGF) (Wako, Osaka, Japan), 10 mM Y-27632 (Wako) and 1% penicillin-streptomycin (Life
Technologies). CEM consists of DMEM:F-12 medium (1:1) (Life Technologies) supplemented with 2%
B-27 (Thermo Fisher Scientific, Waltham, MA), 10 ng/mL KGF (Wako), 10 mM Y-27632 (Wako), and 1% penicillin-streptomycin (Life Technologies).

Quantitative real-time reverse-transcriptase PCR
qRT-PCR was performed using the ABI Prism 7500 Fast Sequence Detection System (Life Technologies) in
accordance with the manufacturer’s instructions. Targets were amplified with TaqMan probe (Life Technologies) assays against ABCB5 (Hs02889060_m1), KRT12 (Hs00165015_m1), PAX6 (Hs00240871_m1), DNp63
(Hs00978339_m1), and GAPDH (Hs99999905_m1). The thermocycling program comprised an initial cycle at
95 C for 20 s, followed by 45 cycles at 95 C for 3 s and 60 C for 30 s.

Flow cytometry and cell sorting
Flow cytometry was performed according to a previously published method (Hayashi et al., 2018). Briefly,
hiPSC-derived SEAMs were dissociated using TrypLE Express (Thermo Fisher Scientific) and re-suspended
in ice-cold keratinocyte culture medium (KCM) (Hayashi et al., 2016, 2017, 2018) supplemented with 5% FBS
(Japan Bio Serum, Hiroshima, Japan). Harvested cells were then stained with 5 mg/13106 cells of mouse
anti-ABCB5 mAb (clone 3C2-1D12) (Ksander et al., 2014; Wilson et al., 2014; Lutz et al., 2016; Schatton
et al., 2015) for 30 min on ice. Following three washes with PBS they were then stained with 1 mg/13106 cells
of Alexa Fluor 647-conjugated secondary antibody (Thermo Fisher Scientific) for 30 min on ice. Cells were
subsequently stained with 0.5 mg/13106 cells of PE-conjugated anti-CD104 (ITGB4; 58XB4, Biolegend,
San Diego, CA), 0.375 mg/13106 cells of FITC-conjugated anti-SSEA-4 (MC813-70, Biolegend), and
0.25 mg/13106 cells of PE-Cy7-conjugated anti-CD200 (OX-104, BD Biosciences, San Diego, CA) antibodies
for 1 hr on ice, followed by three washes with PBS. Cell sorting was performed with a FACSAria II instrument
(BD Biosciences), and the data analyzed using BD FACSDiva Software v8.0.3 (BD Biosciences).

Colony-forming assay (CFA) and holoclone assay (HA)
For the CFA investigation ABCB5+/ABCB5- SEAM-derived corneal epithelial cells that had been isolated by
cell sorting were seeded in 6-well plates onto mitomycin C (MMC)-treated 3T3-J2 feeder cells (kindly provided by Prof H. Green, Harvard Medical School, Boston, MA) in corneal epithelium maturation medium
(CMM; i.e.10% KCM medium containing 10% FBS, 10 ng/mL KGF and 10 mM Y-27632) at a density of 500
cells/well. Following cultivation for 8-10 days, cells were fixed with 10% formaldehyde neutral buffer solution (Wako) and stained with rhodamine B (Wako). Colony-forming efficiency was ascertained by counting
colonies under a dissecting microscope, and colony diameters were measured using ImageJ v1.51k
(National Institutes of Health, Bethesda, MD). For the HAs, ABCB5+/ABCB5- SEAM-derived corneal epithelial cells were cultivated in 6-well plates on 3T3-J2 feeder cells in CMM at a density of 500 cells/well. After
10-13 days, single colonies were picked up under a dissecting microscope. After dissociating the colonies
using TrypLE Express (Thermo Fisher Scientific), the dissociated cells were again seeded on 3T3-J2 feeder
cells and cultivated in CMM for 8-9 days. Colonies were then fixed with 10% formaldehyde neutral buffer
solution (Wako) and stained with rhodamine B (Wako), and viewed under a microscope to classified as holoclones or non-holoclones based on a modification of a previously described method (Hayashi et al., 2016;
Barrandon and Green, 1987). See also Figure S1.

mAb-mediated ABCB5 blockade
Sorted ABCB5+ hiPSC-derived corneal epithelial cells were treated with 50 mg/mL of anti-ABCB5 blocking
mAb (clone 3C2-1D12) (Ksander et al., 2014; Wilson et al., 2014; Lutz et al., 2016; Schatton et al., 2015) for 10
consecutive days from the initial day of sorting. The mAb-mediated ABCB5 blockade was followed by CFAs
and HAs for the treated ABCB5+ hiPSC-derived corneal epithelial cells (Figure 3A).
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Fabrication of ex vivo expanded cell sheets
Fabrication of corneal epithelial cell sheets was accomplished according to previous reports (Hayashi et al.,
2016, 2017). Briefly, ABCB5+/ABCB5- SEAM-derived corneal epithelial cells that had been isolated by cell
sorting were seeded on LN511E8-coated dishes at a density of 3,000-9,600 cells/well (96-well plates or cell
culture inserts) and cultivated in CEM for 21–28 days.

Hematoxylin and eosin (H&E) staining
Corneal epithelial cell sheets generated from hiPSC-derived ABCB5+/ABCB5- cells were embedded in
OCT compound and frozen at 80 C. Thin (10 mm) sections were cut, fixed with 10% formaldehyde neutral
buffer solution (Wako), washed with distilled water and stained with hematoxylin and eosin (H&E).
Following deparaffinization and hydration, they were imaged on a NanoZoomer-XR C12000 (Hamamatsu
Photonics, Hamamatsu, Japan) microscope. The thickness of the H&E stained cell sheets was measured using ImageJ v1.51k (National Institutes of Health) at ten equally spaced positions in individual sheets and the
results were averaged (Figure 4A).

Immunofluorescence staining
Immunofluorescence staining of ABCB5 and KRT12 was performed on unfixed material, whereas staining of
PAX6 and p63 was performed on tissue that had been fixed in cold methanol (Wako) and washed, three
times for 10 min each, with Tris-buffered saline (TBS, TaKaRa Bio, Shiga, Japan). Staining of KRT13 and
MITF was conducted on material that had been fixed in 4% paraformaldehyde (PFA, Wako) and washed
with TBS three times for 10 min each time. All sections were incubated in TBS containing 5% donkey serum
and 0.3% Triton X-100 (Sigma-Aldrich, St. Louis, MO) for 1 hr to block non-specific reactions. Subsequently
they were incubated overnight at 4 C with primary antibodies against ABCB5 (3C2-1D12) (2.5 mg/mL;
Ksander et al., 2014; Wilson et al., 2014; Lutz et al., 2016; Schatton et al., 2015), KRT12 (1:200; N-16; Santa
Cruz Biotechnology, Santa Cruz, CA), PAX6 (1:1200; PRB-278P; Covance Research Products, Denver, PA),
p63 (1:200; 4A4; Santa Cruz Biotechnology), KRT13 (1:200; AE8; Abcam, Cambridge, MA), and MITF
(1:1000; C5; Exalpha Biologicals, Watertown, MA). After three more washes with TBS for 10 min each, samples were incubated with AF488-conjugated secondary antibodies (1:200; Life Technologies) for 1 hr at
room temperature. Counterstaining was performed with Hoechst 33,342 (1:200; Life Technologies) prior
to confocal fluorescence microscopy (FV3000, Olympus Corporation, Tokyo, Japan).

QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
The data are expressed as means G standard deviation (s.d.). The statistical analyses were performed using
the Wilcoxon signed-rank test. All of the statistical analyses were performed using the JMP software program v14.0.0 (SAS institute Inc., Cary, NC). No statistical methods were used to predetermine sample size.
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